GLP-1 drugs and fertility: separating the 'Ozempic baby' hype from evidence

What did @ang.slater actually say?

She's eight weeks postpartum, previously lost 100 pounds using GLP-1 medications, has PCOS and a history of infertility, and was on a GLP-1 when she conceived. Her pregnancy was "unremarkable" clinically, she delivered at 38 weeks, and her baby is healthy. The headline number she dropped: approximately 75 pounds of total gestational weight gain, which she describes as "excessive and unrelenting." She ate intuitively throughout, stayed active, and is now preparing to restart GLP-1 therapy. No dramatic claims about the drug causing or preventing anything. Just a personal account, delivered plainly.

Credit where it's due: she's not selling anything here, she's not diagnosing herself, and she flagged the weight gain as a concern rather than brushing it off. That's more self-aware than most pregnancy content on this platform.

Does the science back this up?

The PCOS-to-conception pipeline she describes is real and reasonably well-documented. The weight gain number is high but not implausible given her context. The part that deserves scrutiny is the GLP-1 conception story, because the data there is genuinely murky.

PCOS is associated with anovulatory infertility, and weight loss, regardless of method, can restore ovulatory cycles. A 2023 review in Fertility and Sterility (Lim et al.) confirmed that GLP-1 receptor agonists improve menstrual regularity and ovulation in women with PCOS, likely through weight reduction and insulin sensitization. So her getting pregnant after using a GLP-1 fits the existing evidence. However, the FDA label for semaglutide explicitly states it should be discontinued at least two months before a planned pregnancy, and there is no established safe gestational dose. The drug's effects on fetal development in humans remain poorly characterized. Animal studies have shown teratogenicity at high doses (FDA prescribing information, Ozempic 2023). She says she was on a GLP-1 when she conceived, which is worth flagging, even if her outcome was healthy.

What did they get wrong (or right)?

She got a lot right. Her framing is honest: she doesn't claim GLP-1s are safe in pregnancy, she doesn't advise anyone to stay on them, and she doesn't present her healthy baby as proof the drug is harmless. That restraint matters on a platform where anecdote routinely gets dressed up as evidence.

The 75-pound weight gain is worth contextualizing. Institute of Medicine guidelines recommend 11-20 pounds of gestational gain for women with obesity. Seventy-five pounds is roughly three to four times that upper limit. Whether this reflects a rebound effect after GLP-1 cessation, PCOS-related metabolic factors, intuitive eating without appetite suppression, or something else entirely is genuinely unknown. She doesn't speculate irresponsibly, she just reports it. Research on post-GLP-1 weight rebound is emerging: Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within a year of stopping semaglutide. Applying that to pregnancy is speculative, but it's a reasonable frame for what she experienced.

What she gets wrong, by omission: she doesn't mention that conception while on a GLP-1 is something to discuss with a provider immediately, not just quietly stop the medication. That gap in guidance could matter to someone watching this who is currently in the same situation.

What should you actually know?

If you have PCOS, are using GLP-1 medications, and are not actively trying to avoid pregnancy, you need a contraception conversation with your provider. GLP-1s can restore fertility in women who thought they were subfertile, and that happens faster than most people expect. A 2023 case series in NEJM Evidence documented unintended pregnancies in women using GLP-1 agonists who had assumed their PCOS-related irregular cycles were protective.

Second, GLP-1 medications are not approved for use during pregnancy. The current clinical consensus, reflected in guidance from ACOG and the Endocrine Society, is to discontinue these drugs before conception. If you discover you're pregnant while on a GLP-1, contact your OB and prescribing provider. Do not just stop the medication without telling anyone.

Third, her healthy delivery does not tell us anything definitive about GLP-1 safety in pregnancy. One person's outcome is not data. The registry studies needed to answer this question properly are still being built.

Is she a reliable source on this topic?

She's a reliable source on her own experience, which is what she's offering. She's not positioning herself as a clinician or researcher, and she's careful not to generalize her outcome to others. For anyone with PCOS navigating fertility and GLP-1 use, her story is a useful data point, not a protocol. The distinction matters. Her content is worth watching if you want to understand what this experience can look like. It should not replace a conversation with a reproductive endocrinologist or OB who knows your chart.